Company Profile

THYROCARE TECHNOLOGIES LTD.

NSE : THYROCAREBSE : 539871ISIN CODE : INE594H01019Industry : Hospital & Healthcare ServicesHouse : MNC
BSE549.954 (+0.73 % )
PREV CLOSE (Rs.) 545.95
OPEN PRICE (Rs.) 547.55
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 549.95 (186 )
VOLUME 74
TODAY'S LOW / HIGH (Rs.)546.85 550.00
52 WK LOW / HIGH (Rs.)519.85 725
NSE548.80 1.7 (+0.31 % )
PREV CLOSE(Rs.) 547.10
OPEN PRICE (Rs.) 547.00
BID PRICE (QTY) 548.80 (5 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 2921
TODAY'S LOW / HIGH(Rs.) 541.00 549.90
52 WK LOW / HIGH (Rs.)524 724

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.41
Dividend Yield(%) 1.82
TTM EPS (Rs.) 19.20
P/E Ratio 28.64
Book Value (Rs.) 78.25
Face Value (Rs.) 10
MCap (Rs. in Mn) 29019.72
Price/Earning (TTM) 25.37
Price/Sales (TTM) 8.23
Price/Book (MRQ) 7.03
PAT Margin (%) 29.00
ROCE (%) 33.55
Incorporation Year : 2000

Management Info :

A Velumani - Chairman A Velumani - Managing Director

Registered Office :

Address : D - 37/1, Ttc Industrial Area,M I D C,Turbhe,
Navi Mumbai,
Maharashtra-400703

Phone : 91-022-27622762

Website : www.thyrocare.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
13Dec12-13-2018$Thyrocare Technologies informs about analyst meet Thyrocare Technologies infor

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Thyrocare Technologies has informed that a team of Fund Managers and Research Analysts of Malabar Investments would be having a meeting with Dr. A. Velumani, Chainnan, Managing Director & CEO, Anand Velumani, Director of the company’s wholly owned subsidiary, Nueclear Healthcare, Dr. Caesar Sengupta, Vice-President-Operations and Sachin Salvi, General Manager-Finance, at the office by 11.00 AM on Monday, December 17, 2018. There could be last minute change in the timings or in the names of the officers the analysts would be meeting. No un-published Price-Sensitive Information will be shared during the above meeting.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disc..
03Dec12-03-2018$Thyrocare Technologies informs about analyst meet Thyrocare Technologies infor

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Thyrocare Technologies has informed that Shrikant Akolkar, Senior Analyst- Pharma of IIFL Securities would be having a meeting with Sachin Salvi, General Manager-Finance, at the office by 11.00 AM on Tuesday, December 04, 2018. There could be last minute change in the names of Analysts or in the timings and Shrikant Akolkar may be accompanied by some of his colleagues, too. It is also informed that no un-published Price-Sensitive Information will be shared during the above meeting.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disc..
03Dec12-03-2018$Thyrocare Technologies informs about investor meet Thyrocare Technologies infor

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Thyrocare Technologies has informed that Robert Harvey and Taizo Ishida, Portfolio Managers of Matthews Asia would be having a meeting with Anand Velumani, Director of the company’s wholly owned subsidiary, Nueclear Healthcare, and Aditya Shinde, Deputy General Manager- Finance at Hotel Trident, BKC by 09.00 AM on Wednesday, December 05, 2018. There could be last minute change in the names of Analysts or in the timings. It is also informed that no unpublished Price-Sensitive Information will be shared during the meetings.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disc..
01Dec12-01-2018$Thyrocare Technologies informs about analyst meet Thyrocare Technologies infor

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Thyrocare Technologies has informed that Anand Velumani, Director of the wholly owned subsidiary, Nueclear Healthcare, and Aditya Shinde, Deputy General Manager- Finance would be participating at B & Ks Investor Conference- Emergent India- 2018 organized by Batlivala & Karani Securities India, at Hotel Trident BKC, Mumbai, on Wednesday, 5th December 2018, where the representatives of various Funds would be meeting, from 10.00 A.M to 6.00 P.M.

The above information is a part of company’s filings submitted to BSE.

 

 

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disc..
09Nov11-09-2018$Thyrocare Technologies informs about conference call Thyrocare Technologies infor

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Thyrocare Technologies has informed that a conference call for the Indian and overseas analysts has been arranged by its management to discuss the Company's financial results for Quarter / Half Year ended September 30, 2018 on Monday, November 12, 2018 at 2.30 P.M. local time. Dr. A. Velumani, Chairman & Managing Director, A. Sundararaju, Executive Director & CFO, Sachin Salvi, General Manager- Finance, and  Anand Velumani, Director, Nueclear I Healthcare, will represent the Company. Dial-in details are given in the copy of enclosed Invite of Prabhudas Lilladher, who is organizing the conference call.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disc..
Financials More
Rs. in Millions
QTR Sep 18 ANNUAL 18
Net Profit265.2960.38
Gross Profit 404.3 1479.64
Operating Profit 440.71626.41
Net Sales 956.83317.94
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Dr Lal Pathlabs (BSE)
 1014.30 (3.02%)
M.Cap ( in Cr)
8453.34
Apollo Hospital Ent. (BSE)
 1348.10 (1.40%)
M.Cap ( in Cr)
18755.46
Dr Agarwals Eye Hsp (BSE)
 389.50 (4.99%)
M.Cap ( in Cr)
183.07
NG Industries (BSE)
 65.40 (3.40%)
M.Cap ( in Cr)
21.91
Shalby Ltd. (BSE)
 146.00 (0.69%)
M.Cap ( in Cr)
1576.94
Shareholding Pattern More
NON-INSTITUTION 8.25 %
PROMOTERS 65.12 %
MUTUAL FUNDS/UTI 14.33 %
FI/BANKS/INSURANCE 0.33 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested